SHIP1 Inhibition As Novel Therapeutic Approach in Chronic Lymphocytic Leukemia
Ecker V, Braun M, Neumayer T, Muschen M, Ruland J, Buchner M. SHIP1 Inhibition As Novel Therapeutic Approach in Chronic Lymphocytic Leukemia. Blood 2018, 132: 894. DOI: 10.1182/blood-2018-99-117053.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaMyeloid-derived suppressor cellsSecondary lymphoid organsImmune cell functionPeripheral bloodCLL cellsLymph nodesMalignant CLL cellsB cellsT cellsImmune responseLymphoid organsLymphocytic leukemiaSmall molecule inhibitorsSHIP1 inhibitionAge-matched healthy donorsAnti-tumor immune responsePharmacological inhibitionCell deathCLL peripheral bloodTreatment-related toxicityImmunoglobulin-producing plasma cellsRegulatory T cellsCell functionCLL cell deathDUSP1/6 Inhibition Reduces Tumor Cells and Activates Immune Response in Chronic Lymphocytic Leukemia
Braun M, Ecker V, Neumayer T, Muschen M, Ruland J, Buchner M. DUSP1/6 Inhibition Reduces Tumor Cells and Activates Immune Response in Chronic Lymphocytic Leukemia. Blood 2018, 132: 2857. DOI: 10.1182/blood-2018-99-117052.Peer-Reviewed Original ResearchPatient-derived peripheral blood mononuclear cellsChronic lymphocytic leukemiaMyeloid-derived suppressor cellsB cell receptorImmunogenic cell deathCLL cellsPrimary CLL cellsB cellsImmune cellsT cellsTreatment optionsImmune responseLymphocytic leukemiaBCI treatmentDonor-derived B cellsAntigen-specific T cell proliferationHematopoietic stem cell transplantationPeripheral blood mononuclear cellsHigh-mobility group box 1 proteinMobility group box 1 proteinCell deathGroup box 1 proteinHyperphosphorylation of ERK1/2Poor-risk diseaseCD8 T cells